Frank McDaniel, Esq.
Founding Shareholder, McDaniel Law Group, PC

Mr. Frank McDaniel is the founding shareholder in the law firm of McDaniel Law Group, PC.  With over 32 years of experience in the practice of corporate, securities and taxation law, he strives to provide cost-effective, common-sense business solutions and innovative legal counsel.  McDaniel’s clients have ranged from early stage to large multinational publicly-traded companies, research institutions and investment firms involved in domestic and international transactions.  More specifically, Mr. McDaniel has developed over the course of his career substantial industry-specific expertise within the fields of biotechnology, pharmaceutical, medical device and other biosciences and healthcare, having provided corporate and taxation legal services in transactions involving well over 100 bioscience companies, clinical research organizations, research institutions and investment capital firms.

More specifically, Mr. McDaniel has extensive experience in the handling of debt and equity financings, including convertible notes and both common and preferred stock; taxable and tax-free mergers and acquisitions; reverse mergers; strategic alliances and partnerships; the formation of corporations, limited liability companies, joint ventures and shareholder arrangements; domestic and international licensing; supply and manufacturing, sales and distribution and product acquisition agreements (principally in the field of the biosciences); noncompetition, nondisclosure and nonsolicitation agreements; nonqualified deferred compensation arrangements, including Sections 409A and 280(g) change-in-control or “parachute”  payments; employment and severance agreements; and stock option and restricted stock plans and agreements.

On behalf of his bioscience clients, Mr. McDaniel has negotiated bio/pharmaceutical and medical device-related domestic and international licensing, supply and manufacturing, sales and distribution and product acquisition agreements for small startups to large multinational and publicly-traded pharmaceutical companies, along with numerous national and international research institutions.  Some of the research institutions with which he has negotiated licenses and other transactional agreements include the Allegheny-Singer Research Institute, Arizona State University, University of Alabama, Baylor University, Centers for Disease Control & Prevention (“CDC”), Columbia University, Cornell University, Duke University, Emory University, Morehouse School of Medicine, Institute of Gustav Roussy, Georgia Institute of Technology, Georgia State University, University of Georgia, University of Massachusetts, North Carolina State University, Ohio State University, Oregon Health & Sciences University, Stanford University, Texas A&M, University of California - Los Angeles, University of California – San Francisco, University of Chicago, University of Florida, University of Pittsburgh, University of Rochester, University of Texas (MD Anderson), University of Texas Medical Branch, Vanderbilt University and Yale University.  His experience includes not only the licensing of such technology, but also the negotiation of material transfer agreements, sponsored research agreements, testing agreements, clinical trial agreements, OEM agreements and other related agreements.

Mr. McDaniel holds a Masters of Laws in Taxation from Emory University.  He was a founding board member and served as the second board chair for the Atlanta Bar Association, Taxation Section.  Mr. McDaniel has also served as an adjunct professor in the Masters of Taxation Program at Georgia State University and Masters of Healthcare Program at Mercer University and has been a frequent speaker for local, state and national forums on topics relating to strategic alliances in the biosciences, mergers and acquisitions, limited liability companies, federal and state taxation and other healthcare-related transactions.

Mr. McDaniel serves as a member of the board of directors for Georgia Bio and chair of the board of directors for BioMed Investor Network, Inc., a biosciences and healthcare-focused angel network.  He is the founder of the Innovation Summit (previously known as the Georgia Life Sciences Summit), for which he served as the chair for three consecutive years.  He is the recipient of the Georgia Bio Industry Growth Award (January 2015) and the Georgia Bio Community Award (2004).  Mr. McDaniel is a co-founder of the Atlanta Business Chronicle's "Healthcare Heroes" annual event.  He has also been recognized by the Atlanta Business Chronicle as one of the "Top 25 Names to Know in Biotechnology" and "Who's Who in Health Care" in the Atlanta metropolitan area.  Mr. McDaniel is also the author of three publications:  “The Life Sciences Industry – Surviving the Toughest of Times Through Venture Funding and Strategic Alliances” – Health Law Handbook, Spring 2003; “The Emerging Field of Biotechnology:  Investigating The Legal Issues” – Health Law Handbook, Spring 2002; “Integrated Delivery Systems in the Healthcare Industry” – Research Institute of America Tax-Exempt Organizations, Spring 1995.